Setmelanotide for the Treatment of Acquired Hypothalamic Obesity (TRANSCEND) @NEJMgroup
Setmelanotide for the Treatment of Acquired Hypothalamic Obesity (TRANSCEND) @NEJMgroup
Uploaded July 2026 | Updated September 2026, 2 weeks ago
Among participants 4 to 66 years of age with acquired hypothalamic obesity, setmelanotide, a melanocortin-4 receptor agonist, led to significantly greater reductions in body-mass index and hunger than placebo at 52 weeks. Read the full TRANSCEND trial results at NEJM.org.
Setmelanotide for the Treatment of Acquired Hypothalamic Obesity (TRANSCEND)NEJM This Week β€” May 7, 2026Meet the EquationDr. Glaucomflecken Explains: Triple-Antihypertensive Pill after Intracerebral Hemorrhage (TRIDENT)Intention to Treat: The Race Equation (Audio Preview)Review Article: Antidotes for Anticoagulation Reversal (Key Points)Leading Transformation in Rural Health: How Mayo Clinic Health System Is Redefining Care, Culture...NEJM Interview: Jatin Vyas on the effect of corporatization of academic medical centers on medica...Images in Clinical Medicine: Vibrio vulnificus Necrotizing Soft-Tissue InfectionImage Challenge β€” April 23, 2026Intention to Treat: When Race Matters (Promo)Are E-Cigarettes Really Safe?
NEJM Group |

Setmelanotide for the Treatment of Acquired Hypothalamic Obesity (TRANSCEND)

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER